105381-95-1 Usage
Uses
Used in Biochemical Research:
3-(3-Pyridyl)-DL-alanine is utilized as a substrate for the assay of chymotrypsin-like activity, providing a means to measure the activity of enzymes that are crucial in various biological processes.
Used in Drug Development:
Due to its distinctive chemical properties, 3-(3-Pyridyl)-DL-alanine is employed in the development of new drugs, where its unique structure may offer novel therapeutic avenues.
Used in Cancer Therapy:
3-(3-Pyridyl)-DL-alanine has demonstrated potential applications in cancer therapy, possibly due to its ability to interact with specific biological targets or pathways that are relevant to cancer cell behavior, making it a candidate for further exploration in oncology research.
Check Digit Verification of cas no
The CAS Registry Mumber 105381-95-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,5,3,8 and 1 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 105381-95:
(8*1)+(7*0)+(6*5)+(5*3)+(4*8)+(3*1)+(2*9)+(1*5)=111
111 % 10 = 1
So 105381-95-1 is a valid CAS Registry Number.
105381-95-1Relevant academic research and scientific papers
Anthranilic acid based CCK1 receptor antagonists: Preliminary investigation on their second "touch point"
Varnavas, Antonio,Lassiani, Lucia,Valenta, Valentina,Mennuni, Laura,Makovec, Francesco,Hadjipavlou-Litina, Dimitra
, p. 563 - 581 (2007/10/03)
In this phase of structure-affinity relationship study of VL-0395, a new anthranilic acid based CCK1 selective antagonist, we propose a series of unnatural aminoacidic derivatives. The result of this work is the identification of a new CCK ligand, which possesses an affinity (IC50 = 35 nm) one order of magnitude greater than the lead and, as a general rule, it points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Hence, the modification of the C-terminal pharmacophoric group of our lead VL-0395 can not only enhance the affinity of anthranilic acid derivatives but can modulate the selectivity for one CCK receptor subtype or afford mixed antagonists.
